Cognision

We’re demonstrating our High-Performance, Easy-to-Use Polysomnography (PSG) System at CNS Summit today Nov. 11 at 5-7 PM … ??VISIT US at the Poster Session (poster #18) to see a demo of our new PSG system. The new, validated PSG solution will allow us to conduct full Level 2 clinical grade sleep studies that are easy to implement in CNS clinical trials with minimal staff training. Level 2 PSG means that the system can collect a variety of physiological measures: - Brain activity (EEG) - Eye movements (EOG) - Muscle activity (EMG) - Heart rate (ECG) - Blood oxygen level - Breathing patterns - Airflow - Snoring - Body position - Leg movement The fully-automated analysis will allow clinical trial researchers to obtain results in a timely manner for all of our biomarkers (PSG, EEG, ERP). Also learn about our standardized testing approach and automated analysis for EEG/ERP biomarkers at the poster session (developed in collaboration with EEG/ERP Biomarker Qualification Consortium). #neuroscience #clinicaltrials #clinicalresearch #mentalhealth #sleep #biomarkers

We’re attending CNS Summit in Boston Nov. 10-13! … Visit our poster (#18) on Nov. 11 at 5-7 PM: “Standardized EEG/ERP battery for measuring drug effects in CNS trials using end-to-end automated analytic pipeline” We’ll also be showing our new High-Performance, Easy-to-Use Polysomnography (PSG) System. Meet our team to discuss how EEG, ERP, & PSG biomarkers can enhance CNS clinical trials & drug development: K.C. Fadem Founder & Chief Technology Officer Igor Korolev, DO, PhD ?? VP, Neuroscience & Digital Helath Nathan Alvarado Director, Business Development #neuroscience #mentalhealth #clinicalresearch #clinicaltrials #pharmaceuticals #digitalhealth

Congratulations to Anavex Life Sciences on the successful Phase IIb/III study of Blarcamesine (ANAVEX2-73) in Alzheimer’s disease! We’re proud to have worked with Anavex nearly 10 years ago to integrate EEG/ERP biomarkers into their Phase IIa clinical trial. Check out the poster presented at AAIC 2015 showing that the P300 is sensitive to Blarcamesine’s effects and predictive of its clinical efficacy in patients with Alzheimer’s disease. Our longstanding collaboration with Anavex shows the power of EEG/ERP biomarker-guided approach to CNS drug development using the COGNISION System. ??CONTACT US to learn how EEG/ERP measures can be used as CNS biomarkers in drug development. #neuroscience #mentalhealth #clinicalresearch #pharmaceuticals #alzheimers #clinicaltrials

Congratulations to Anavex Life Sciences on their exciting results on Blarcamesine (ANAVEX2-73) Phase IIb/III study in Alzheimer’s disease! Blarcamesine is a dual Sigma-1 / muscarinic receptor agonist with benefits on neurodegeneration and cogniton according to latest data presented at CTAD. We’re proud to have worked with Anavex nearly 10 years ago to integrate EEG/ERP biomarkers into their Phase IIa clinical trial. This study showed that the P300 is sensitive to Blarcamesine’s effects and predictive of its clinical efficacy in patients with Alzheimer’s disease. We’re excited to continue working with Anavex on their ANAVEX3-71 drug for schizophrenia, with encouraging preliminary EEG/ERP biomarker results. Check out the results presented at AAIC 2015 below! Our collaboration with Anavex shows the power of EEG/ERP biomarker-guided approach to CNS drug development using the COGNISION System. ??CONTACT US to learn how EEG/ERP measures can be used as CNS biomarkers in drug development. #neuroscience #mentalhealth #alzheimers #clinicaltrials #clinicalresearch #biomarkers

EXCITING NEWS: We’re expanding our clinical trial capabilities to include PSG (Polysomnography)-based sleep studies in addition to EEG/ERP biomarkers. The new, validated PSG solution will allow us to conduct full Level 2 clinical grade sleep studies that are easy to implement in clinical trials with minimal staff training. Level 2 PSG means that the system can collect a variety of physiological measures: - Brain activity (EEG) - Eye movements (EOG) - Muscle activity (EMG) - Heart rate (ECG) - Blood oxygen level - Breathing patterns - Airflow - Snoring - Body position - Leg movement The fully-automated analysis will allow clinical trial researchers to obtain results in a timely manner for all of our biomarkers (PSG, EEG, ERP). Sleep-related abnormalities are associated with a variety of brain and mental health conditions, including Alzheimer’s disease, depression, traumatic brain injury, and schizophrenia. PSG-based sleep biomarkers can be useful in clinical trials and CNS drug development. ??LEARN MORE and partner with us by reaching out to our team via our website or LinkedIn. #neuroscience #clinicaltrials #clinicalresearch #mentalhealth #sleep #biomarkers

???? September 21 is World Alzheimer’s Day The future of Alzheimer’s disease / dementia care is bright with emerging preventive, diagnostic, and treatment approaches. We partner with clinicians, scientists, and pharma / biotech companies to leverage validated EEG/ERP biomarkers for Alzheimer’s disease / dementia assessment, research, and drug development. Check out the published studies in this area using the COGNISION? system for EEG/ERP biomarkers: 1. “A clinical trial to validate event-related potential markers of Alzheimer's disease in outpatient settings” - https://lnkd.in/gJWuHEST 2. “The use of event related potentials to predict amyloid PET status among patients from a memory disorders clinic” - https://lnkd.in/gEyQKpzr ??LEARN MORE: Visit our website / contact our team. #neuroscience #alzheimers #mentalhealth #biotechnology #clinicaltrials #clinicalresearch

??Our ISCTM Poster: “Standardized EEG/ERP battery for measuring drug effects in CNS trials using end-to-end automated analytic pipeline” We hope this work, done in collaboration with EEG/ERP Biomarker Qualification Consortium (EBQC), will promote the adoption & standardization of EEG/ERP biomarkers in interventional clinical trials. Cognision is a member of the EBQC, along with diverse industry stakeholders, including pharmaceutical companies. #neuroscience #mentalhealth #clinicalresearch #clinicaltrials #pharmaceuticals #digitalhealth

We’ll be at International Society for CNS Clinical Trials & Methodology (ISCTM) Autumn Conference in San Diego, CA this week presenting a poster (#33) as part of EEG/ERP Biomarker Qualification Consortium: “Standardized EEG/ERP battery for measuring drug effects in CNS trials using end-to-end automated analytic pipeline” (??Link to Poster in Comments) Meet our team at ISCTM, including: - Igor Korolev, DO, PhD ??, VP of Neuroscience & Digital Health - Nathan Alvarado, Director of Business Development ???? SCHEDULE MEETING and learn how EEG/ERP biomarkers could enhance CNS clinical trials — please contact Nathan via LinkedIn or email (nalvarado [at] cognision [dot] com) #neuroscience #mentalhealth #clinicalresearch #clinicaltrials #pharmaceuticals #biotechnology

Our team is at Alzheimer’s Association International Conference (#AAIC24) in Philadelphia USA this week! ??Learn how EEG/ERP biomarkers could enhance your company’s clinical trials — reach out to Igor Korolev, DO, PhD ??, VP of Neuroscience & Digital Health, and schedule a time to meet at AAIC. #neuroscience #alzheimers #mentalhealth #clinicalresearch #clinicaltrials #digitalhealth

?? [RESEARCH STUDY]: ERP biomarkers measured via COGNISION System predict Amyloid PET status in patients with memory complaints BACKGROUND: Amyloid positron emission tomography (PET) scans provide in vivo evidence of Alzheimer’s disease (AD); however, their high cost limits their use in standard clinical care. Event related potentials (ERPs) may represent an inexpensive and non-invasive additional method for detecting AD pathology. OBJECTIVE: We investigated whether ERPs, along with neuropsychological data, serve as predictors of amyloid PET status in patients with memory complaints. METHODS: Veterans aged 50–100 were recruited from a memory disorders clinic. Participants underwent a neuropsychological battery and an ERP auditory oddball protocol, including 28 patients with a positive amyloid PET scan, and 39 patients with a negative scan. RESULTS: ERP-P200 target amplitude and P200 standard latency were predictors of amyloid PET status. ROC analysis showed that P200 standard latency exhibited the highest sensitivity (86%) and specificity (72%) in predicting amyloid PET status (AUC = 0.84). CONCLUSIONS: ERP-P200 measures are strong indicators of amyloid-β presence in patients from a memory disorder clinic. Increased P200 amplitude and decreased P200 latency in patients with a positive amyloid PET scan may be attributed to hyperactivation of perceptual bottom-up processes compensating for AD-related synaptic loss in the fronto-parietal networks. ??ARTICLE (Link in Comments): Marin, Anna et al. (2024). The Use of Event Related Potentials to Predict Amyloid PET Status Among Patients from a Memory Disorders Clinic. Journal of Alzheimer’s Disease. #neuroscience #clinicalresearch #alzheimers #cognition #digitalhealth #biomarkers